Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13910106 | 0.94 | ALDH1A1 (0.54) | PTPN1LMNABCHEMAOBNPC1 | |
| SCHEMBL4591147 | 0.94 | BCHE (0.56) | BCHEMAOBNPC1RAB9AATM | |
| SCHEMBL2821924 | 0.94 | BCHE (0.56) | BCHEMAOBNPC1RAB9AATM | |
| SCHEMBL8249953 | 0.93 | GFER (0.56) | KMT2AGFERLMNARAB9A | |
| SCHEMBL2824404 | 0.92 | KDM4E (0.49) | PTPN1KMT2ABCHEMAOBNPC1 | |
| SCHEMBL4589756 | 0.92 | KDM4E (0.49) | PTPN1KMT2ABCHEMAOBNPC1 | |
| SCHEMBL8259525 | 0.89 | SMN1; SMN2 (0.51) | KMT2ABCHEMAOBMAPT | |
| SCHEMBL936129 | 0.88 | BCHE (0.53) | KMT2ABCHEMAOBRAB9A | |
| SCHEMBL2825700 | 0.87 | NPC1 (0.56) | PTPN1LMNAHTTBCHEMAOB | |
| SCHEMBL8259627 | 0.85 | RAB9A (0.49) | KMT2ABCHEMAOBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685105-B1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2008-10-15 | — | — | EP | claimed |
| EP-1893200-B1 | CARBAMATE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2010-09-29 | — | — | EP | disclosed |
| US-20090082399-A1 | Carbamate derivatives as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2009-03-26 | — | — | US | disclosed |
| US-20090082399-A1 | Carbamate derivatives as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2009-03-26 | — | — | US | disclosed |
| WO-2006123244-A2 | CARBAMATE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082399-A1 | Carbamate derivatives as positive allosteric modulators of metabotropic glutamate receptors | GRM5, GRIK5, GRM1 | PTPN1 508/4885KMT2A 1223/4885GFER 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.